@article{ee7dde4c36b74eeda85efdb5b5af02b7,
title = "Entorhinal and transentorhinal atrophy in mild cognitive impairment using longitudinal diffeomorphometry",
abstract = "Introduction Autopsy findings have shown the entorhinal cortex and transentorhinal cortex are among the earliest sites of accumulation of pathology in patients developing Alzheimer's disease. Methods Here, we study this region in subjects with mild cognitive impairment (n = 36) and in control subjects (n = 16). The cortical areas are manually segmented, and local volume and shape changes are quantified using diffeomorphometry, including a novel mapping procedure that reduces variability in anatomic definitions over time. Results We find significant thickness and volume changes localized to the transentorhinal cortex through high field strength atlasing. Discussion This demonstrates that in vivo neuroimaging biomarkers can detect these early changes among subjects with mild cognitive impairment.",
keywords = "Braak staging, Diffeomorphometry, Entorhinal cortex, Longitudinal analysis, Mild cognitive impairment, Shape analysis",
author = "{for the} and {Alzheimer's Disease Neuroimaging Initiative} and Tward, {Daniel J.} and Sicat, {Chelsea S.} and Timothy Brown and Arnold Bakker and Michela Gallagher and Marilyn Albert and Michael Miller",
note = "Funding Information: Funding: This work was supported by the National Institutes of Health [grant number P41 EB015909 ]; the National Institute on Aging [grant number R01 AG048349 ]; the Phyllis F. Albstein Fund; and the Kavli Neuroscience Discovery Institute. Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DODADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc; Cogstate; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to supportADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California. Funding Information: This work used the Extreme Science and Engineering Discovery Environment (XSEDE) [45] , which is supported by the National Science Foundation grant number ACI-1548562. Publisher Copyright: {\textcopyright} 2017 The Authors",
year = "2017",
doi = "10.1016/j.dadm.2017.07.005",
language = "English (US)",
volume = "9",
pages = "41--50",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
}